President Bush Names Niederhuber NCI Director

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

President Bush has appointed John E. Niederhuber, MD, as director of the National Cancer Institute (NCI). He is the Institute's 13th director, succeeding Andrew C. von Eschenbach, MD, who has been nominated as commissioner of the Food and Drug Administration (FDA).

WASHINGTON—President Bush has appointed John E. Niederhuber, MD, as director of the National Cancer Institute (NCI). He is the Institute's 13th director, succeeding Andrew C. von Eschenbach, MD, who has been nominated as commissioner of the Food and Drug Administration (FDA).

Dr. Niederhuber brings a wealth of experience to NCI, as a former cancer center director, former chair of the National Cancer Advisory Board (NCAB), member of the Institute's senior management team for the last year, and acting NCI director since June 2006. In addition to his NCI administrative duties, Dr. Niederhuber holds a clinical appointment as a member of the medical staff at the NIH Clinical Centers.

Dr. Niederhuber joined NCI in September 2005 as deputy director for translational and clinical sciences and almost immediately became NCI's chief operating officer after Dr. von Eschenbach was named FDA acting director.

Dr. Niederhuber came to NCI from the University of Wisconsin School of Medicine, where he served as professor of surgery and oncology and as director of its Comprehensive Cancer Center from 1997 to 2002. Dr. Niederhuber earned his medical degree at Ohio State University School of Medicine, Columbus.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content